Using an autophosphorylation membrane assay, we examined activation of kinases in dierent organs after intraperitoneal injections of mitogens and cytokines into mice. In the multiple organs examined administration of either epidermal growth factor (EGF), phorbol 12-myristate 13-acetate (PMA) or interleukin-1b (IL-1b) activated a number of kinases. Most notably among those was a kinase of approximately 85 kDa (p85) that was activated by EGF, PMA and IL-1b in the lung, kidney, brain, liver and heart. The size and properties of this enzyme are indistinguishable from the RING3 kinase that has a very high activity in leukocytes of patients with leukemia. In animals treated with PMA, antibodies against RING3 kinase immunoprecipitated PMA-responsive p85 activity from the lung and brain suggesting that p85 and RING3 kinases are the same enzymes. Activation of p85/RING3 kinase by growth factors in multiple organs might re¯ect involvement of this enzyme in the pathogenesis of leukemias and other proliferative diseases.
Growth factors and cytokines induce cellular responses as diverse as cell proliferation and programmed cell death. Inducible protein kinases are key intracellular transducers that allow growth factors and cytokines to signal these events. For more than a decade inducible protein kinases have been intensely studied not only because these enzymes play a key role in normal cellular responses but also because these kinases are thought to play an important role in neoplastic transformation and in¯ammation (Levitzki, 1996) . Because only a few studies have examined activation of protein kinases in whole organisms, the current knowledge about inducible kinases is largely based on work that has been done in cell cultures. Studies of inducible kinases in whole animals are necessary in order to bridge the gap that currently exists between the knowledge of kinase activation derived from cell cultures and our understanding of the role of these enzymes in health and disease. In that regard, whole animals studies are particularly important for elucidating signal transduction pathways and kinase cascades that are activated in response to environmental or dietary inducers, including carcinogens.
Many dierent methods have been introduced to identify inducible protein kinases. We have previously used an autophosphorylation membrane assay to identify growth factor-inducible renaturable kinases (Ferrell and Martin, 1989) . Using this method we originally identi®ed a serine/threonine 85 kDa (p85) nuclear kinase in cultured lymphocytes that was responsive to interleukin-1a (IL-1a), interferon-g (IFN-g) and lipopolysaccharide (LPS) (Rachie et al., 1993) . As with many other growth factor-responsive kinases (Seger and Krebs, 1995) , p85 kinase is activated by phosphorylation. p85 kinase properties are identical to the recently identi®ed nuclear serine/ threonine RING3 kinase (Beck et al., 1992; Denis and Green, 1996) . Like p85, RING3 kinase is renaturable, it autophosphorylates, it is activated through phosphorylation and it is responsive to a variety of growth factors including IL-1 (Denis and Green, 1996) . Both p85 and RING3 kinases are very active in leukocytes of patients with acute and chronic leukemias. In one leukemic patient in remission the activity of the RING3 kinase in leukocytes returned to normal, suggesting that RING3 kinase may be involved in the pathogenesis of this disease (Denis and Green, 1996) .
To determine the distribution of renaturable kinases in intact organs, we partially puri®ed homogenates from several mouse organs and assayed each preparation for renaturable kinase activity using a membrane kinase assay (Ferrell and Martin, 1989) . This method was previously used to identify mitogen-and cytokineresponsive kinases in cultured cells (Ferrell and Martin, 1989; Rachie et al., 1993; Denis and Green, 1996) . Figure 1 shows the distribution of at least ®ve renaturable kinases (50, 60, 68, 85 and 200 kDa) in mouse brain, lung, kidney, heart and liver. Most notably, all tissues examined contain an 85 kDa kinase (p85) that appears to have the highest activity in brain (lane 1) and lung (lane 2), but is also present in kidney (lane 3), heart (lane 4), and liver (lane 5).
A number of growth factors and cytokines such as EGF (Laurence and Gusterson, 1990) and IL-1 (Dinarello, 1991) activate protein kinases in cultured cells. Pharmacological agents such as the tumor promoting agent, PMA, have proven to be useful not only in studying tumorigenesis but also in exploring signal transduction pathways (O'Brian and Ward, 1989) . We administered EGF, PMA and IL-1b into mice and examined the autophosphorylation activity of renaturable kinases (Figures 2 and 3 ). Systemic administration of EGF into mice (10 mg/g body weight, 10 min) stimulated the p85 kinase activity in all tissues examined. There was a large increase (3 ± 4-fold) of p85 activity in homogenates of lung, kidney and liver and a small (1.3 ± 1.5-fold) increase of p85 kinase activity in heart and brain homogenates. PMA administration (400 pmol/g body weight, 30 min) also stimulated p85 in all tissues (Figures 2 and 3) . It substantially stimulated p85 kinase in the lung (3.5-fold) and the kidney (2.5-fold), but less so in the liver, heart and brain (1.5-fold). Like EGF and PMA, IL-1b administration (4 pmol/g body weight, 60 min) stimulated p85 kinase most potently in the lung (2.9-fold), while the p85 stimulation in kidney, liver, heart and brain was approximately 1.3 ± 1.8-fold (Figures 2 and  3) .
In addition to the stimulation of p85 renaturable kinase activity by EGF, PMA and IL-1b, several other renaturable kinases were stimulated by these treatments. In the lung, all three treatments stimulated the activity of p68, p60 and p50 kinases. Similarly, in the kidney EGF and PMA stimulated p68, p60 and p50; but IL-1b administration did not activate these kinases. In the liver, other than p85, only p68 was stimulated by EGF, PMA and IL-1b treatment. In brain, the most notable change was the decrease in the p50 activity observed after the treatment of animals with IL-1b.
Treatment of cultured cells with cytokines stimulates p85 kinase activity in the nucleus but not in the cytoplasm (Rachie et al., 1993) . To determine the subcellular localization of activated p85 kinase after intraperitoneal administration of growth factors, we prepared cytoplasmic and nuclear extracts from hepatocytes of mice treated with an intraperitoneal injection of EGF ( Figure 4 ). For these studies we chose the liver because, among the organs that we examined (Figures 2 and 3), liver is best suited for harvesting cells and for making cytoplasmic and nuclear extracts (Ru-Jamison et al., 1993 Alpini et al., 1994) . We chose EGF because in the liver it was the most potent inducing agent (Figures 2 and 3) . Results from these experiments showed that there is constitutive activity of p85 kinase in the cytoplasm (lane 1) and the nucleus (lane 4). Ten min after treatment of animals with an intraperitoneal injection of EGF, there was greater induction of p85 kinase activity in the nucleus than in the cytoplasm (compare lanes 2 and 5). In both the cytoplasmic (lane 3) and nuclear extracts (lane 6) the p85 kinase activity diminished to near baseline after 30 min of EGF treatment. These results demonstrate that unlike cells grown in culture (Rachie et al., 1993) , cells harvested from the liver contain a constitutively active cytoplasmic and nuclear renaturable p85 kinase activity. However, the EGF-responsive induction of p85 kinase in the nuclear fraction is greater than that in the cytoplasmic fraction (compare lanes 2 and 5).
Recently, a cDNA encoding an 83 kDa renaturable, serine/threonine kinase (RING3) was characterized in cultured cells. RING3 kinase is stimulated by treatment of cell cultures with a number of agents including IL-1 (Beck et al., 1992; Denis and Green, 1996) . In HeLa cells RING3 kinase is exclusively nuclear and is activated by phosphorylation. Like p85, RING3 kinase also autophosphorylates after denaturation and renaturation on membranes. To determine if RING3 (Denis and Green, 1996) and p85 kinase (Rachie et al., 1993) are the same or related enzymes, Alpini et al., 1994) . 200 ± 300 mg of frozen tissues were homogenized by two 15-seconds-cycles with a Polytron in homogenization buer (25 mM TrisHCl, pH=7.5, 100 mM b-glycerophosphate, 25 mM p-nitrophenol phosphate, 5 mM orthovanadate, 10 mM MgCl 2 , 2 mM EGTA, 2 mM EDTA, 5 mM benzamidine, 1 mM PMSF, 10 mg/ml leupeptin). Tissue homogenate were mixed with DEAE-Sephacel beads and proteins were eluted with 200 mM NaCl in 20 mM HEPES, pH=7.5, 2 mM EGTA, 2 mM EDTA, 100 mM b-glycerophosphate, 25 mM p-nitrophenol phosphate, 5 mM orthovanadate, 10 mM MgCl 2 , 2 mM EGTA, 2 mM EDTA, 5 mM benzamidine, 1 mM PMSF, 10 mg/ml leupeptin. 50 mg of the partially puri®ed homogenate from brain (lane 1), lung (lane 2), kidney (lane 3), heart (lane 4) and liver (lane 5) were boiled in 2 6 loading buer (120 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, and 10% bmercaptoethanol) (1 : 1 vol/vol) for 10 min. Proteins were separated by 10% SDS-polyacrylamide gel electrophoresis. After bathing the gel in transfer buer for 30 min proteins were electroblotted to an Immobilon-P membrane in transfer buer (25 mM Tris-HCl, pH 8.2, 192 mM glycine, 20% methanol and 0.005% SDS). Blotted proteins were denatured for 30 min at room temperature by incubating the Immobilon-P membrane in 10 ml of denaturing buer (7M guanidine HCl, 50 mM Tris, 30 mM DTT, 3.0 mM EDTA, pH 8.3). Blotted proteins were then allowed to renature by incubating the membrane in renaturation buer (150 mM NaCl, 50 mM Tris, 2.0 mM EDTA, 2.0 mM DTT, 0.05% Tween-20, pH 7.4) for 12 ± 14 h at 48C. After renaturation, membranes were incubated in phosphorylation buer (50 mM Tris pH 7.5, 5 mM MgCl 2 , 5 mM MnCl 2 , 5 mM DTT and 50 mCi [g-32 P]ATP) for 30 min at room temperature. Phosphorylation was terminated by washing membranes 4 ± 5 times in 50 mM Tris (pH 7.6)/0.05% Tween-20. After the last wash membranes were brie¯y submerged in 100% methanol, stained with 0.1% Amido Black (b), air-dried and autoradiographed (a) p85/RING3 kinase J Ostrowski et al we prepared anti-RING3 antibodies for immunoprecipitation experiments. Mice were treated for various times with intraperitoneal injection of PMA and tissue homogenates were prepared from the lungs and the brain as before (Figure 1 ). The immune but not the pre-immune anti-RING3 kinase antibodies immunoprecipitated p85 kinase ( Figure 5 ). Its autokinase activity was stimulated in animals treated with PMA with a peak stimulation between 30 ± 60 min. In addition, a 60 kDa kinase co-immunoprecipitated with p85. Immunoprecipitation of p85 from brain homogenates showed activation kinetics of p85 similar to that seen in the lung, and it also revealed coimmunoprecipitation of a 60 kDa protein. p85 but not p60 kinase phosphorylates hnRNP K protein (Van Seuningen et al., 1995) , suggesting that p60 is not simply a degradation product of p85 (data not shown). These results strongly suggest that p85 kinase is either the same as or related to RING3 kinase. These results also suggest that there is a pool of p85/RING3 kinase that exists in a complex with a p60 kinase. This ®nding is consistent with the observation that p85 kinase copuri®es with a p60 autokinase activity from lymphocytes of leukemic patients, and the observation that partially puri®ed p85 kinase exists in a large complex (unpublished observations). p85/RING3 kinase is activated by phosphorylation (Rachie et al., 1993; Denis and Green, 1996) . The phosphorylated residues that are responsible for its induction have not been mapped but the activation of p85/RING3 kinase could be mediated by serine/ threonine, tyrosine or dual-speci®city kinase(s) (Hunter, 1991) . p85/RING3 kinase could either be phosphorylated/activated in the cytoplasm and then translocate to the nucleus or p85/RING3 kinase may be activated in the nucleus. In cultured cells the activated form of p85/RING3 kinase is predominantly nuclear (Rachie et al., 1993; Denis and Green, 1996) . In insect cells nearly all exogenously expressed RING3 kinase is nuclear as well (data not shown). Although in the liver most of the p85 kinase activity is found in Figure 2 Stimulation of renaturable kinases in the lung, brain, kidney, liver, and heart after systemic administration of EGF, PMA and IL-1b into mice. After intraperitoneal injection (10 ml per gram of body weight) of 0.9% saline or 0.9% saline containing either EGF (1 mg/ml)(10 min), PMA (4610 75 M)(60 min), or IL-1b (4610 77 M)(30 min) mice were sacri®ced, organs were harvested, homogenates were prepared and kinase activities were assayed as described in Figure 1 . Shown are membrane kinase assay from three control animals (lanes 1 ± 3) and three animals treated with either EGF (lanes 4 ± 6), PMA (lanes 7 ± 9), or IL-1b (lanes 10 ± 12) Figure 3 Measurement of p85 kinase autophosphorylation activity in dierent mouse tissues after systemic administration of mitogens. The 32 P signal of the 85 kDa band (Figure 2 ) from kidney, liver, brain, heart and lung from control animals, and animals treated with EGF, PMA and IL-1b was measured with a phosphoimager. Data represent mean+s.d. (n=3 animals). Values were normalized to control animals p85/RING3 kinase J Ostrowski et al nuclear extracts, a fraction of the kinase activity pool can also be found in cytoplasmic extracts (Figure 4 ). These observations suggest that at least a fraction of p85/RING3 kinase pool is activated by a nuclear kinase.
EGF, PMA and IL-1 activate a myriad of known protein kinases one or more of which could be responsible for the activation of p85/RING3 kinase. Three parallel MAP kinase cascades have been identi®ed in mammalian cells; ERK(MAPK), JNK(SAPK) and p38/RK cascades (Seger and Krebs, 1995; Tibbles et al., 1996) . The MAPK/ERK cascade can be triggered by many extracellular ligands including EGF and PMA (Seger et al., 1992; Seger and Krebs, 1995) and treatment of cells with growth factors leads to the translocation of this enzyme to the nucleus (Chen et al., 1992; Lenormand et al., 1993) . Among ERK(MAPK) targets the pp90 RSK is particularly relevant because, like ERK(MAPK), it also translocates to the nucleus in response to treatment of cells with mitogens (Chen et al., 1992) . While EGF activates the ERK(MAPK) cascade, both JNK(SAPK) and p38/RK kinase cascades are triggered by IL-1 (Bird et al., 1994; Freshney et al., 1994; Lee et al., 1994) . JNK(SAPK) has been reported to translocate to the nucleus (Kawaskai et al., 1996) where it phosphorylates the transcription factors c-Jun and ATF-2 (Derijard et al., 1994; Gupta et al., 1995) but is likely to have multiple other nuclear targets. p38/RK has not been reported to translocate to the nucleus but one of its targets, the MAPKAP-2 kinase does (Stokoe et al., 1992) . Because they all can signal the nucleus, one or more of the parallel MAP kinase cascades could activate p85/RING3. Regardless of whether one of the known kinase cascades considered above or an unknown pathway targets p85/RING3 kinase, the system described here provides an opportunity to explore activation of a kinase cascade(s) in whole animals. The ability to assess activation of kinase cascades in dierent intact organs simultaneously should prove to be particularly useful.
In summary, this study demonstrates that systemic administration of mitogenic and in¯ammatory agents into mice stimulates activity of p85/RING3 kinase in a number of organs. Given the fact that p85/RING3 kinase is activated by phosphorylation, results of this study provide an opportunity to examine signal transduction and activation of kinase cascades in multiple organs in vivo. Moreover, results of these Hepatocytes from male mice were obtained by the two-stage perfusion method (Alpini et al., 1994) . At given time points after intraperitoneal injection of EGF, mice were anaesthetized by ether, the abdominal cavity was opened and the liver was ®rst perfused via the portal vein with calcium-free buer (140 mM NaCl, 5.4 mM KCl, 2.5 mM EGTA, 25 mM HEPES-NaOH, pH=7.5) at 1 ml/ min for 10 min at 378C. Next, the liver was reperfused with the buer containing 140 mM NaCl, 5.4 mM KCl, 5 mM CaCl 2 , 25 mM HEPES-NaOH, pH=7.5 and 0.5 mg collagenase/ml at¯ow rate 1 ml/min for 15 min at 378C. After softening, the liver was mechanically dispersed in PBS, ®ltered through 100 mm nylon mesh, followed by three washes with PBS and centrifugation at 50 g (2 min, 48C). Cell viability, as determined by trypan blue exclusion, was over 85%. Cytoplasmic and nuclear extracts were prepared as described previously for the measurement of p85 kinase activity in cultured cells (Rachie et al., 1993) 1 At given time points mice were sacri®ced, organs were harvested and tissue homogenates were prepared (Figure 1 ). 200 mg of proteins in immunoprecipitation (IP) buer (150 mM NaCl, 50 mM TrisHCl, pH=7.5, 5 mM EGTA, 1% Triton X-100, 0.5% NP-40, 2 mM EDTA, 20 mM b-glycerophosphate, 30 mM p-nitrophenol phosphate, 0.2 mM orthovanadate, 10 mM MgCl 2 , 2 mM EGTA, 20 mM NaF, 5 mM benzamidine, 1 mM PMSF, 10 mg/ml leupeptin) were incubated with pre-immune or immune anti-RING3 kinase chicken antibody for 2 h. Immune-1 was raised against N-terminal RING3 peptide (GCG-VSNPKKPGRVTNQ) conjugated to bovine serum albumin. Immune-2 was raised against GST-RING3 fusion protein. After incubation with the primary antibody 20 ml of agarose beads bearing anti-chicken IgY antibodies were added and the samples were mixed by rotating for another 1 h at 4 C. Following binding beads were washed four times with IP buer and proteins were eluted from beads by boiling in 2 6 loading buer. Eluted proteins were resolved by SDS ± PAGE, transferred to Immobilon-P membrane. Blotted proteins were phosphorylated on the membrane and analysed by autoradiography as before (Figure 1) studies may re¯ect involvement of p85/RING3 kinase in diseases where abnormal cell proliferation is responsible for the pathological process. Involvement of p85/RING3 kinase in mitogenic intracellular pathways is consistent with the observation that the activity of this enzyme is very high in leukocytes from patients with acute and chronic leukemia.
